Pear Therapeutics, Inc. is a commercial-stage healthcare company. The Company is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases. Its products include reset, reSET-O and Somryst. The Company's reset product is indicated for the treatment of substance use disorder (SUD) related to alcohol, cannabis, cocaine and stimulants, such as monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The Company's Somryst product is the only software-based and guideline-recommended treatment for chronic insomnia. The Company’s pipeline consists of 14 product candidates, including candidates in psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal (GI), oncology, and cardiovascular. The Company focuses on psychiatric and neurologic conditions.